Based on the Crispr Therapeutics AG stock forecast from 11 analysts, the average analyst target price for Crispr Therapeutics AG is USD 77.60 over the next 12 months. Crispr Therapeutics AG’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Crispr Therapeutics AG is Bullish , which is based on 8 positive signals and 3 negative signals. At the last closing, Crispr Therapeutics AG’s stock price was USD 47.26. Crispr Therapeutics AG’s stock price has changed by -5.08% over the past week, -3.39% over the past month and -30.06% over the last year.
No recent analyst target price found for Crispr Therapeutics AG
No recent average analyst rating found for Crispr Therapeutics AG
Company Overview Crispr Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. Read Less
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing techno...Read More
Frequently Asked Questions About Crispr Therapeutics AG (CRSP) Stock
Based on ratings from 11 analysts Crispr Therapeutics AG's stock is Buy . Stock Target Advisor's fundamental analysis is Bullish . The stock has 9 buy, 1 sell and 5 hold ratings.
Unfortunately we do not have enough data on CRSP's stock to indicate if its a good dividend stock.
Based on targets from 11 analysts, the average taret price for CRSP is USD 77.60 over the next 12 months. The maximum analyst target price is USD 105 while the minimum anlayst target price is USD 30.
CRSP stock's Price/Earning ratio is 13.53.
Our analysis grades CRSP stock's Price / Earning ratio at F. This means that CRSP stock's Price/Earning ratio is above 63% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CRSP may be a overvalued for its sector.
The last closing price of CRSP's stock was USD 47.26.
The most recent market capitalization for CRSP is USD 4.03B.
Based on targets from 11 analysts, the average taret price for CRSP is projected at USD 77.60 over the next 12 months.
This means that CRSP's stock price may go up by +64.20% over the next 12 months.
We can't find any ETFs which contains Crispr Therapeutics AG's stock.
As per our most recent records Crispr Therapeutics AG has 407 Employees.
Crispr Therapeutics AG's registered address is Baarerstrasse 14, Zug, Switzerland, 6300.
You can get more information about it from Crispr Therapeutics AG's website at https://www.crisprtx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Crispr Therapeutics AG (CRSP) Stock
Based on ratings from 11 analysts Crispr Therapeutics AG's stock is Buy . Stock Target Advisor's fundamental analysis is Bullish . The stock has 9 buy, 1 sell and 5 hold ratings.
Unfortunately we do not have enough data on CRSP's stock to indicate if its a good dividend stock.
Based on targets from 11 analysts, the average taret price for CRSP is USD 77.60 over the next 12 months. The maximum analyst target price is USD 105 while the minimum anlayst target price is USD 30.
CRSP stock's Price/Earning ratio is 13.53.
Our analysis grades CRSP stock's Price / Earning ratio at F. This means that CRSP stock's Price/Earning ratio is above 63% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CRSP may be a overvalued for its sector.
The last closing price of CRSP's stock was USD 47.26.
The most recent market capitalization for CRSP is USD 4.03B.
Based on targets from 11 analysts, the average taret price for CRSP is projected at USD 77.60 over the next 12 months.
This means that CRSP's stock price may go up by +64.20% over the next 12 months.
We can't find any ETFs which contains Crispr Therapeutics AG's stock.
As per our most recent records Crispr Therapeutics AG has 407 Employees.
Crispr Therapeutics AG's registered address is Baarerstrasse 14, Zug, Switzerland, 6300.
You can get more information about it from Crispr Therapeutics AG's website at https://www.crisprtx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CRSP !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
